Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Stock Investor Wire

GILD Quote, Trading Chart, Gilead Sciences Inc.


home / stock / gild / gild quote

$65.24 Last:

0.96% Change Percent:

$64.51 Open:

$65.24 Previous Close:

$65.35 High:

$63.96 Low:

2,356,288 Volume:

03/08/2021 11:10:19 am Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2021-03-0864.5165.2465.3563.962,356,288
2021-03-0563.4264.6264.74563.39,748,500
2021-03-0462.863.2364.5462.5315,745,171
2021-03-0362.788962.7563.3262.177,032,406
2021-03-0262.49563.0163.5962.356,836,236
2021-03-0161.7662.4662.6361.657,326,219
2021-02-2662.7861.462.7961.3910,387,737
2021-02-2563.7762.7963.9762.517,663,682
2021-02-2463.5663.7164.2362.816,523,061
2021-02-2363.8563.6864.1662.788,701,996
2021-02-2263.9364.1164.4763.5256,552,037
2021-02-1965.0864.3765.2264.276,030,512
2021-02-1864.8665.2365.4664.336,102,297
2021-02-1764.333565.165.1463.847,691,487
2021-02-1666.4164.866.664.529,707,988
2021-02-1566.7866.8967.2766.363,977,653
2021-02-1266.7866.8967.2766.363,967,202
2021-02-1167.266.9267.266.055,778,925
2021-02-1067.2667.2968.3267.17,572,231
2021-02-0967.7767.367.8466.85046,605,884
Stock Information

Gilead Sciences Inc. Company Name:

GILD Stock Symbol:

NASDAQ Market:

Gilead Sciences Inc. Website:

GILD Quote, Trading Chart, Gilead Sciences Inc.

MENU
GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board
Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...

Stock Investor Wire
RECENT GILD NEWS
  • GILD - Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma

    -- Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients -- -- Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts -- Kite, a Gilead Com...

  • GILD - Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program

    A large part of a $5 billion bet that Gilead Sciences (NASDAQ: GILD) made in 2019 has fallen apart in late clinical-stage development. The bottom fell out from under ziritaxestat, a new drug candidate Gilead Sciences was developing in partnership with Galapagos (NASDAQ: GLPG) ...

  • GILD - Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF

    Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.



Sign up or login to continue

Sign up or login to continue.


Forgot password?




WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News